文献速递间质性肺疾病

右美沙芬联合吡非尼酮增强肺纤维化疗效

Add-On Dextromethorphan Improves the Effects of Pirfenidone in Bleomycin-Treated Mice and Patients With Pulmonary Fibrosis.
PubMed 文献 · Respirology · 2025-04-13

该研究在博来霉素诱导的小鼠肺纤维化模型、TGF-β1诱导的细胞模型及肺纤维化患者中,评估右美沙芬(DM)联合吡非尼酮(PFD)的抗纤维化效果。结果显示超低剂量DM通过恢复氧化还原平衡减轻小鼠肺纤维化,临床研究中加用DM可改善PFD对肺功能下降的延缓作用及胸部高分辨率CT评分。

要点

  • 超低剂量DM单用或联用PFD在小鼠中均显示显著抗纤维化保护作用。
  • DM通过抑制NADPH氧化酶4/活性氧产生并上调超氧化物歧化酶恢复氧化还原平衡。
  • 临床研究中加用DM可增强PFD延缓肺功能下降和改善胸部HRCT评分的效果。

核心结论

  • 超低剂量右美沙芬通过恢复氧化还原平衡显著减轻博来霉素诱导的小鼠肺纤维化。
  • 加用右美沙芬可增强吡非尼酮在博来霉素处理小鼠和肺纤维化患者中的疗效。

研究设计与样本

  • 研究包含博来霉素诱导的小鼠肺纤维化模型、转化生长因子-β1诱导的细胞模型及肺纤维化患者的临床研究。
  • 小鼠模型评估纤维化面积、羟脯氨酸水平及纤维化标志物。
  • 细胞模型分析增殖、迁移、纤维化标志物及氧化应激。
  • 临床研究比较PFD组与PFD+DM组治疗前后肺部影像评分和肺功能。
  • 试验注册号:ChiCTR2000037602。

主要发现

  • 超低剂量DM单用或联合PFD在博来霉素小鼠中均显示显著保护作用。
  • 博来霉素造模后2周给予DM或联合药物仍显示抗纤维化效果。
  • 体外实验中DM单药及联合治疗通过抑制NADPH氧化酶4/活性氧产生并上调超氧化物歧化酶恢复氧化还原平衡。
  • 临床研究中加用DM改善了PFD延缓肺功能下降和改善胸部高分辨率CT成像评分的效果。

临床怎么用

  • 对于肺纤维化患者,在吡非尼酮治疗基础上加用右美沙芬可能进一步延缓肺功能下降并改善胸部高分辨率CT评分。
  • 右美沙芬的超低剂量用法及长期安全性需进一步研究确认。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVE: Idiopathic pulmonary fibrosis is a progressive interstitial lung disease characterised by excessive activation of myofibroblasts. However, currently available antifibrotic drugs exhibit limited efficacy. The dysregulation of redox processes plays a significant role in the pathogenesis of idiopathic pulmonary fibrosis. Dextromethorphan (DM) is used in the treatment of various inflammation-related diseases. This study aimed to investigate the effectiveness of the combination of DM and pirfenidone (PFD) in treating idiopathic pulmonary fibrosis in both animal models and humans. METHODS: In a bleomycin-induced pulmonary fibrosis mouse model, the anti-fibrotic effects of DM and/or PFD were assessed by evaluating fibrotic area, hydroxyproline levels, and fibrotic markers. In a transforming growth factor-β1-induced cell model, proliferation, migration, fibrosis markers, and oxidative stress were analysed to elucidate the mechanisms underlying the anti-fibrotic actions of DM and/or PFD. Finally, the efficacy of DM combined with PFD in patients with pulmonary fibrosis was evaluated by comparing pulmonary imaging scores and pulmonary function before and after treatment in the PFD group and the PFD + DM group. RESULTS: We observed that even ultralow doses of DM, either alone or in combination with PFD, demonstrated substantial protective effects in mice. Notably, administration of DM or combined drugs at 2 weeks after bleomycin modelling still showed anti-fibrotic effects. In vitro, DM monotherapy and combination therapy restored the redox balance by suppressing nicotinamide adenine dinucleotide phosphate (NADPH) oxidase 4/reactive oxygen species production and upregulating superoxide dismutase, contributing to their anti-fibrotic mechanisms. In the clinical study, add-on DM improved PFD in mitigating pulmonary function decline and improving chest high-resolution computed tomography imaging scores. CONCLUSIONS: Ultralow doses of dextromethorphan significantly alleviate pulmonary fibrosis in bleomycin-treated mice through restoring the redox balance. Add-on DM improves the effects of PFD in both bleomycin-treated mice and patients with pulmonary fibrosis. TRIAL REGISTRATION: ChiCTR2000037602.

来源:Respirology,查看原文。版权归原作者所有。

引用

  1. Huang J, Liu N, Jin Y, et al. Add-On Dextromethorphan Improves the Effects of Pirfenidone in Bleomycin-Treated Mice and Patients With Pulmonary Fibrosis. Respirology. 2025. PMID: 40223283. doi:10.1111/resp.70043

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。